Project: Development of a companion diagnostic for use with SOL101 in the treatment of Fragile X Syndrome

Acronym FXSFIX (Reference Number: 10197)
Duration 01/03/2016 - 01/09/2018
Project Topic FXSFIX will deliver a diagnostic biomarker for use with SOL101, a clinical candidate drug for the treatment of Fragile X Syndrome (FXS). SOL101 is a first in class drug for FXS which is an orphan disease with no current clinically available treatments. SOL101 is an inhibitor of p70 S6 kinase 1 (S6K1), a protein recently shown to have utility in the control of aberrant protein production which is a phenotypic hallmark of FXS and will aim to reverse the symptoms suffered by patients.
Network Eurostars 2
Call Eurostars Cut-Off 4

Project partner

Number Name Role Country
23216 Sentinel Oncology Limited Coordinator United Kingdom
23217 NMI TT GmbH Partner Germany